Pacritinib and Nerandomilast: Interaction Details

Brand names
Pacritinib
Vonjo
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

Nerandomilast

We don't have a drug information page for Nerandomilast yet. Have a question about Nerandomilast? Ask a pharmacist, free →

What Happens When You Take Pacritinib With Nerandomilast

What can happen when they are taken together (rated Major)

Reduced nerandomilast exposure and reduced of nerandomilast

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Nerandomilast is a , so giving it together with a moderate CYP3A could lower its exposure and thereby weaken its efficacy. A drug interaction study tested this using bosentan (a moderate CYP3A inducer) at 125 mg twice daily for 3 days.

With bosentan, nerandomilast fell by 15% and fell by 41%. The steady-state trough concentration (Ctrough,ss) of nerandomilast is predicted to drop by roughly 58%. When a moderate CYP3A inducer is used at the same time, the recommended nerandomilast dosage is 18 mg twice daily, and the dose should not be lowered to 9 mg twice daily.1

The Pacritinib and Nerandomilast Interaction, Explained

Pacritinib may lower the amount of nerandomilast in your body. Pacritinib can speed up the liver enzyme () that breaks nerandomilast down, so less of it stays in your blood. That could make nerandomilast work less well for your lung condition.

In a study with a similar enzyme-speeding drug, nerandomilast levels dropped by about 41% overall. Your care team knows how to handle this. The nerandomilast label gives a specific dose to use when it is taken with this type of medicine. Please don't change or stop either medicine on your own. Ask your pharmacist or doctor to review your doses.

Mechanism: (pacritinib, classed here as a moderate CYP3A ) increases CYP3A-mediated of nerandomilast, a CYP3A . Direction: decreased nerandomilast exposure and potentially reduced .

  • Magnitude (bosentan, moderate inducer, 125 mg BID x 3 days): down 15%, down 41%. Predicted Ctrough,ss down about 58%.
  • Evidence: probable. Onset unspecified. Severity: major.
  • Management: use nerandomilast 18 mg twice daily with moderate CYP3A . Do not reduce to 9 mg twice daily. Monitor clinical response.

See the 1 reference behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Pacritinib and Nerandomilast Interact

The likely mechanism

of -mediated of nerandomilast

In short: Pacritinib speeds up CYP3A, an enzyme that breaks down nerandomilast, so nerandomilast can be cleared faster.
How Drug Interactions Work See this kind of interaction drawn out, step by step, in “When One Drug Lowers Another’s Level”, one chapter of our one-minute explainer. See how it works 

How to Manage the Pacritinib and Nerandomilast Interaction

Your care team can manage this by using the dose recommended for people taking a moderate .

  • The documented recommendation is nerandomilast 18 mg twice daily while taking it with this kind of medicine.
  • The dose should not be lowered to 9 mg twice daily.
  • Keep taking both medicines as prescribed, and do not change doses yourself.
  • Tell your pharmacist or prescriber about all your medicines, and report any worsening of your symptoms. Your team may monitor you more closely.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Pacritinib or Nerandomilast need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

1 report from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Prescribing information: JASCAYD oral tablets, nerandomilast oral tablets

    In a drug interaction study, of nerandomilast with bosentan (a moderate ) at 125 mg twice daily for 3 days lowered nerandomilast by 15% and by 41%. The steady-state trough concentration of nerandomilast (Ctrough,ss) is predicted to fall by roughly 58%.1

Pacritinib and Nerandomilast: Common Questions

How serious is the Pacritinib and Nerandomilast interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Pacritinib and Nerandomilast interaction managed?

Your care team can manage this by using the dose recommended for people taking a moderate . The documented recommendation is nerandomilast 18 mg twice daily while taking it with this kind of medicine. The dose should not be lowered to 9 mg twice daily. Keep taking both medicines as prescribed, and do not change doses yourself. Tell your pharmacist or prescriber about all your medicine… Management is individual — always follow your own care team's guidance.

Does taking Pacritinib and Nerandomilast at different times of day help?

No. Taking them at different times of day does not prevent this one. Pacritinib speeds up , an enzyme that breaks down nerandomilast, so nerandomilast can be cleared faster. That change lasts while pacritinib is being taken and can continue for a while after the last dose.

Your pharmacist or prescriber can tell you how they will manage it.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Ask About the Pacritinib and Nerandomilast Interaction

Ask in your own words about taking Pacritinib and Nerandomilast together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (1)

  1. Product Information: JASCAYD® oral tablets, nerandomilast oral tablets. Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, 2026. DailyMed
Was this write-up helpful?

Other Serious Interactions of Pacritinib and Nerandomilast

Also serious with Pacritinib

Also serious with Nerandomilast

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Pacritinib

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven. This interaction.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.